Oramed Pharmaceuticals Inc (ORMP)

[Billy987]

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

-Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system
-Oramed has already been granted this patent in the United States and Japan

NEW YORK, January 5, 2022 – Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the European Patent Office has granted the Company a patent titled “Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same.” The patent supports Oramed’s oral protein delivery platform technology which underlies its lead drug candidate ORMD-0801 now in pivotal Phase 3 studies and positioned to potentially be the first oral insulin capsule on the market. The granted patent covers a unique method for the purification of raw protease-inhibiting materials which are a key component of the platform technology that protects therapeutic proteins in the digestive system.

“With this newly granted patent, we now have 88 patents granted and 35 more pending, further fortifying Oramed’s leading position with respect to intellectual property assets addressing the oral delivery of therapeutic proteins currently only available via injection,” stated Oramed CEO Nadav Kidron.

https://mailchi.mp/oramed/oramed-granted-key-european-patent-for-platform-technology-in-oral-delivery-of-proteins?fbclid=IwAR0QixyCkpm_LfP9c7bfQcQm3UFSHwLEvpuSoYWFOeGdksEgPA-2-7Bxays